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A22 WHOLE DEGRADOME EXPRESSION PROFILING IN
NORMAL AND OSTEOARTHRITIC CARTILAGE
T.E. Swingler1, R.K. Davidson1, J.G. Waters1, C. Darrah2, A. Cooper2,
S.T. Donell2, I.M. Clark1. 1University of East Anglia, Norwich, UNITED
KINGDOM, 2Norfolk & Norwich University Hospital, Norwich, UNITED
KINGDOM
Purpose: Cartilage destruction in osteoarthritis (OA) is thought to be
mediated by extracellular proteases. The main focus of research to date
has been on the role of two enzyme families; the matrix metalloproteases
(MMPs) with respect to cartilage collagen breakdown, and enzymes
from the ‘a disintegrin and metalloprotease domain with thrombospondin
motifs’ (ADAMTS) family with respect to cartilage aggrecan loss. It is
now known that there are around 561 proteases in the human genome
(the ‘degradome’): 21 aspartyl, 148 cysteine, 186 metallo-, 178 serine
and 28 threonine proteases. The expression of the vast majority of these
genes in cartilage is unknown. We have therefore proﬁled the complete
degradome in cartilage from patients with either OA or fracture to the
neck of femur (NOF), giving a more complete picture of proteolysis in
this tissue and disease.
Methods: Cartilage was collected at total hip replacement surgery and
snap frozen in liquid nitrogen. Cartilage was ground under liquid nitrogen
in a freezer mill and RNA puriﬁed by a combination of TRIzol (Invitrogen)
and RNeasy (Qiagen). RNA was reverse transcribed and gene expression
assessed by quantitative real-time PCR using Taqman low density arrays
on the ABI Prism 7900.
Results: Expression of 560 proteases and inhibitor genes was detectable
in cartilage using this methodology. Preliminary analysis shows that
approximately 197 proteases are differentially expressed in OA cartilage
compared to NOF at a statistical signiﬁcance of p< 0.05 (79 metallo-,
50 serine-, 41 cysteine-, 6 aspartyl-, 2 threonine proteases and 19
protease inhibitors). At a signiﬁcance of p< 0.0001, there were 3 aspartyl,
14 cysteine, 15 metallo-, 12 serine proteases and 5 inhibitors which are
differentially regulated in OA.
Conclusions: This is the most comprehensive analysis of protease gene
expression in cartilage to date. It has identiﬁed several protease genes
not previously reported to be expressed or regulated in cartilage and
provides the foundation on which to build functional studies.
A23 EXPRESSION OF HTRA1 IN HUMAN OA CHONDROCYTES
LEADS TO MATRIX DEGRADATION, INHIBITION OF MATRIX
SYNTHESIS, AND THE EXPRESSION OF A HYPERTROPHIC
PHENOTYPE
P.G. Mitchell, M.A. Carozza, J. Brittain, D.D. McKinley, K.L. Dufﬁn,
E. Zhen, S. Chandrasekhar, Y-W. Qian, A. Boodhoo. Eli Lilly,
Indianapolis, IN, USA
Purpose: Expression of the serine proteinase HtrA1 is upregulated in hu-
man osteoarthritic (OA) cartilage. To understand the link between HtrA1
expression and pathology, the enzyme was both overexpressed in normal
bovine chondrocytes, and knocked-down in human OA chondrocytes. The
effects of overexpression and knockdown of HtrA1 on 35S incorporation
into the extracellular matrix, and on the expression of genes related to
hypertrophy, were monitored. Finally, peptides resulting from treatment
of human aggrecan with recombinant HtrA1 were determined via mass
spectrometry.
Methods: Bovine chondrocytes and human OA chondrocytes (joint re-
placement surgery), were isolated by sequential digestion with protease
type XIV (Sigma) and collagenase type II (Worthington). Overexpression
of HtrA1 was obtained via electroporation using Amaxa technology. Gene
expression was determined via Taqman analysis using speciﬁc primer
probe sets for each gene. Aggrecan synthesis was determined by plating
chondrocytes on Cytostar T plates in the presence of 5mCi 35S, and
then measuring incorporation of label into the matrix on a Wallac Trilux
scintillation counter. siRNA transfections of human chondrocytes were
carried out using Dharmafect 4 lipid at 0.4 ml/well of 96 well plates.
SmartPool HtrA1 siRNA and non-targeting control siRNA (NT3) were from
Ambion. Enzyme digests of human aggrecan were carried out with HtrA1
(1:20 ratio) in Tris/NaCl/CaCl2, pH 7.5 buffer over a 7 day period with
fresh enzyme added on Day 3.
An LTQ ion trap mass spectrometer with a Surveyor HPLC system
(ThermoFinnigan) was used for peptide identiﬁcation. MS/MS spectra
were searched against protein databases using both Sequest and X!
Tandem database searching algorithms
Results: Taqman analysis of RNA derived from one healthy and 7 human
OA cartilage samples demonstrated a similar disease-associated upreg-
ulation of HtrA1 mRNA as had been previously reported. Treatment of
bovine chondrocytes with recombinant HtrA1 led to decreased 35S sulfate
incorporation into the extracellular matrix. No recovery of 35S sulfate
incorporation was observed up to 5 days post-removal of HtrA1. Overex-
pression of HtrA1 in bovine chondrocytes led to an expression-related
decrease in matrix 35S sulfate incorporation. HtrA1 overexpression in
bovine chondrocytes also led to hypertrophic gene expression changes,
including increases in expression of ADAMTS-5 and cathepsin K, and
a decrease in expression of type II collagen. HtrA1 siRNA treatment of
human OA chondrocytes led to >95% reduction in HtrA1 mRNA. This
was accompanied by signiﬁcant increases in both basal and BMP-7
induced incorporation of 35S sulfate into the cell matrix. MS/MS analysis
of recombinant HtrA1 digests of human aggrecan identiﬁed 28 distinct
peptides.
Conclusions: These studies demonstrate that expression of HtrA1 in
chondrocytes has functional consequences with respect to the ability of
chondrocytes to form and maintain an appropriate extracellular matrix,
and a correctly differentiated phenotype. HtrA1 can potentially act either
directly or indirectly to: (1) degrade extracellular matrix proteins such as
aggrecan, (2) inhibit matrix synthesis, and (3) upregulate expression of a
hypertrophic phenotype. These data suggest that inhibition of HtrA1 activ-
ity in cartilage is a useful therapeutic objective for treating osteoarthritis.
A24 INHIBITION OF MATRIX METALLOPROTEINASES
ENHANCES IN VITRO REPAIR OF THE MENISCUS
A. McNulty1, J.B. Weinberg2, F. Guilak1. 1Duke University Medical
Center, Durham, NC, 2Duke University and VA Medical Centers,
Durham, NC, USA
Purpose: Damage or injury of the meniscus is associated with the onset
and progression of knee osteoarthritis. Previous studies have shown that
the intrinsic repair capacity of the meniscus is inhibited by inﬂammatory
cytokines, such as interleukin 1 (Il-1). The goal of this study was to in-
vestigate the role of matrix metalloproteinases (MMPs) on the integration
of juxtaposed meniscal tissue in an inﬂammatory microenviroment. Using
an in vitro meniscal repair model system, we examined the hypothesis
that inhibition of MMPs in the presence of Il-1 will enhance the repair of
meniscal lesions.
Methods: Explants (8mm diameter, 3mm thick) were harvested from the
outer one-third of porcine medial menisci. To simulate a full-thickness tear,
a 4mm diameter central core was punched out and reinserted. Explants
were cultured for 14 days at 37ºC, 5% CO2 in the presence of 100 pg/mL
recombinant porcine Il-1 alpha and the following MMP inhibitors (EMD
Biosciences): GM 6001, which is a broad spectrum MMP inhibitor, MMP-2
inhibitor I, MMP-2/MMP-9 inhibitor I, MMP-3 inhibitor II, MMP-8 inhibitor I,
and MMP-13 inhibitor. At the end of the culture period, the interfacial
shear strength of the repair was determined using a push-out test. Total
speciﬁc MMP activity in the media was also assessed using a quenched
ﬂuorescent peptide.
Figure 1. GM 6001 inhibits IL-1 mediated MMP activity. Total speciﬁc MMP
activity in the culture media over time was measured using a quenched
ﬂuorescent substrate (n = 10−12 samples per treatment group). The bars
indicate the mean ﬂuorescence units normalized by the wet weight of
the meniscal tissue ± standard error. a: p< 0.05 compared to all other
treatments. b: p< 0.005 compared to GM 6001. c: p< 0.005 compared to
IL-1 + GM 6001 and GM 6001.
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Figure 2. GM 6001 increases meniscal shear strength in the presence
of IL-1. The interfacial shear strength of repair was measured after treat-
ment of meniscal repair model explants with control media, 100 pg/mL
IL-1, 100 pg/mL IL-1 and 200 ng/mL GM 6001, and 100 pg/mL IL-1 and
200 ng/mL GM 6001 negative control (NC GM 6001) for 14 days (n = 9−11
explants per treatment group). The bar indicate the mean shear strength
in kPa + standard error. a: p< 0.0005 compared to control. b: p< 0.05
compared to IL-1 + GM 6001.
Results: Over time in culture there was a slight increase in MMP activity
in control explants, while Il-1 treatment progressively increased MMP
activity (Figure 1). On the other hand, in the presence of Il-1, the broad
spectrum MMP inhibitor GM 6001 signiﬁcantly suppressed MMP activity
in the media (p< 0.005). MMP activity was also reduced in the presence of
Il-1 by the MMP-3 and MMP-8 inhibitors (p< 0.05). Treatment of meniscal
repair model explants with Il-1 signiﬁcantly decreased the shear strength
of repair, as compared to control explants (Figure 2, p< 0.0005). In the
presence of Il-1, GM 6001 increased the shear strength of repair 2.3-
fold over Il-1 treated explants alone (p< 0.05). However, individual MMP
inhibitors did not alter the shear strength of repair in either the presence
or absence of Il-1.
Conclusions: We found that MMPs are responsible for approximately
50% of the Il-1 mediated inhibition of meniscal healing, as shown by
broad-spectrum inhibition of MMP activity. These results suggest that Il-1
may inhibit meniscal repair through the upregulation of MMPs, but the
inhibition of multiple MMPs is necessary to promote integrative meniscal
repair in vitro and potentially in vivo following joint injury or during arthritis.
A25 THE ACUTELY ACL INJURED KNEE ASSESSED BY MRI:
MORPHOMETRIC CHANGE OF CARTILAGE OVER THE
FIRST TWO YEARS AFTER INJURY
R.B. Frobell1, R. Buck2, E.M. Roos1, M-P. Hellio Le Graverand2,
H.P. Roos1, S.L. Lohmander1. 1Clinical Sciences, Lund, Lund,
SWEDEN, 2Pﬁzer Global research & development, Ann Arbor, MI, USA
Purpose: To investigate morphometric change of cartilage in cMF and
TrF over the ﬁrst two years after acute ACL injury.
Methods: In this longitudinal MRI analysis we assessed a consecu-
tive sub-set of subjects included in an RCT of surgical versus non-
surgical treatment after acute ACL injury (The KANON study). 29 patients
(29 knees, 21 males) with a not more than 4 weeks old ACL rupture
were assessed by MRI and underwent similar extensive rehabilitation. 19
of these subjects (mean age 28, 95%CI, 26−30 y) in addition underwent
an ACL reconstruction within 7w from injury, while 10 (mean age 25,
95%CI 21−29 y) were treated with rehabilitation alone. MRI scans were
performed using a 1.5 T imager with a circular polarized surface coil at
baseline, 3 and 24 months after injury. A quantitative analysis was per-
formed where a multi-spectral image data set was created and computer
analyzed. To avoid artefact bias (i.e. ﬁxation material in group treated with
ACL reconstruction), change was measured from 3 to 24 months. We
quantiﬁed cartilage volume (VC), thickness (ThCcAB) and surface area
(AC) in cMF and TrF. Change was reported as mean change, percent
change and standard response mean (SRM, mean change divided by
the standard deviation of change).
Results: In cMF, cartilage morphometry measures increased from
3−24 months after injury (0.052<SRM>0.750). Mean cartilage thickness
and volume increased with 4.2% (95%CI, 2.1−6.3) and 4.5% (1.8−7.2)
respectively. Thickness increased more in knees treated with ACL recon-
struction than in knees treated with rehabilitation alone, 5.6% (2.8−8.4)
and 1.6% (−1.3−4.4), respectively. In TrF, mean measures decreased
(−0.430<SRM>−0.133). AC of TrF decreased (2.7%, 1.2−4.2) in knees
treated with ACL reconstruction but increased (1.2%, −0.4−2.7) in those
treated with rehabilitation alone (Table 1).
Conclusions: Cartilage hypertrophy of cMF, indicated by increased ThC-
cAB and VC, occurs during the ﬁrst 24 months after ACL injury. An early
ACL reconstruction appears to be associated with morphometric change
of cartilage in cMF and TrF after 2 years, where SRMs close to 1 were
observed.
Table 1: Mean change of cartilage surface area (AC), thickness (ThCcAB) and volume (VC)
between 3 and 24 months
All subjects (N=29) Rehab alone (n = 10) ACL reconstruction (n = 19)
Change mean
(95%CI)
Change %
mean
(95%CI)
SRM Change mean
(95%CI)
SRM Change mean
(95%CI)
SRM
AC (mm2)
cMF 1.8
(−11.5, 15.0)
0.4
(−1.1, 1.8)
0.052 −3.7
(−26.9, 19.6)
−0.114 4.6
(−13.0, 22.2)
0.126
TrF −32.0
(−60.3, −3.7)
−1.4
(−2.6, −0.1)
−0.430 24.0
(−6.4, 54.3)
0.566 −61.4
(−95.6, −27.1)
−0.864
ThCcAB (mm)
cMF 0.09
(0.04, 0.14)
4.2
(2.1, 6.3)
0.750 0.03
(−0.03, 0.1)
0.333 0.12
(0.06, 0.18)
0.923
TrF −0.02
(−0.08, 0.04)
−0.5
(−2.9, 1.8)
−0.133 0.02
(−0.02, 0.07)
0.286 −0.04
(−0.13, 0.04)
−0.235
VC (mm3)
cMF 65.4
(17.8, 113.0)
4.5
(1.8, 7.2)
0.522 16.0
(−39.0, 71.1)
0.208 91.4
(24.3, 158.4)
0.657
TrF −88.5
(−215.0, 37.9)
−1.2
(−3.9, 1.5)
−0.267 71.1
(−27.3, 169.5)
0.517 −172.6
(−353.4, 8.3)
−0.460
A26 C/EBP-BETA PROMOTES HYPERTROPHIC
DIFFERENTIATION OF CHONDROCYTES THROUGH
TRANSACTIVATION OF P57KIP2 DURING ENDOCHONDRAL
OSSIFICATION
F. Kugimiya, M. Hirata, S. Ohba, N. Kawamura, T. Ogasawara,
Y. Kawasaki, T. Ikeda, K. Nakamura, U.I. Chung, H. Kawaguchi.
Sensory & Motor System Medicine, Univ. of Tokyo, Tokyo, JAPAN
Purpose: Although hypertrophic differentiation of chondrocytes is a cru-
cial step not only for physiological skeletal growth but also for pathological
disorders like osteoarthritis, the underlying molecular mechanism remains
unclear. This study investigated the role of CCAAT/enhancer-binding
protein b (C/EBPb), a multi-functional transcription factor, in chondrocytes
during endochondral ossiﬁcation.
Methods: To clarify the physiological function of C/EBPb, we initially
compared the skeletal phenotypes of homozygous C/EBPb-deﬁcient
(C/EBPb−/−) mice with those of the wild-type littermates (E16.5) by
Alizarin red, Alcian blue, von Kossa stainings, as well as type X collagen
(COL10) immunostaining and BrdU labeling. We further compared the
proliferation and hypertrophic differentiation in cultures of primary chon-
drocytes derived from ribs of the two genotype littemates by XTT assay,
real-time RT-PCR for COL10, MMP-13, VEGF, and ALP and Alizarin red
stainings. We also compared the same parameters between cultured
wild-type rib chondrocytes with retroviral overexpression of C/EBPb and
the control empty vector. The effect of the C/EBPb overexpression on
cell cycle was examined by a DNA histogram using a ﬂow cytometric
analysis. Identiﬁcation of transcriptional targets of C/EBPb was performed
by a microarray analysis, and was conﬁrmed by real-time RT-PCR. In
vivo expressions of C/EBPb and the target factor were examined by
immunohistochemistry in the mouse growth plates. Transcriptional activity
was examined using HuH-7 cells transfected with a luciferase-reporter
gene construct containing a 1 kb fragment of the promoter. The speciﬁc
binding of the identiﬁed region was veriﬁed by electrophoretic mobility shift
assay (EMSA). Functional relevance was examined by gene silencing by
the small interfering RNA (siRNA).
Results: The C/EBPb−/− mice exhibited dwarﬁsm with an elongated
proliferative zone and delayed chondrocyte hypertrophy in the growth
plate cartilage. The loss- and gain-of-functions of C/EBPb in cultured
chondrocytes revealed that C/EBPb was essential for suppression of
cell proliferation and promotion of hypertrophic differentiation, probably
by accelerating the exit from the cell cycle. The C/EBPb overexpression
caused accumulation of cells in the G0/G1 fraction, and a microarray
analysis identiﬁed several cell cycle factors as the transcriptional targets.
Among them, p57Kip2, a cyclin-dependent kinase inhibitor, was most
strongly up-regulated by the C/EBPb overexpression and down-regulated
